**Circular RNA cir-ITCH Promotes Osteosarcoma Migration and Invasion through cir-ITCH/miR-7/EGFR Pathway**

Hongbo Li, MD1, Min Lan, MD1, Xingen Liao, MD1, Zhiming Tang, MD1, and Chunli Yang, MD1

**Abstract**

Recent studies have suggested that circular RNAs play an important role in the progression of various cancers. We aimed to investigate the possible role of cir-ITCH in osteosarcoma. In this study, we performed experiments with the human osteoblast cell line hFOB1.19 and several osteosarcoma cancer cell lines and the results showed that the expression of cir-ITCH in osteosarcoma cancer cell lines was significantly upregulated compared to that in the human osteoblast cell line. In addition, the results showed that cir-ITCH could promote the migration, invasion, and growth of osteosarcoma cells. Further mechanistic studies revealed that cir-ITCH could enhance epidermal growth factor receptor (EGFR) expression by reducing the level of miR-7. Increased EGFR phosphorylation was found to be concomitant with high expression of EGFR. We determined that cir-ITCH-mediated increase in the migration and invasion of osteosarcoma cells was dependent on EGFR phosphorylation. In conclusion, our research uncovered an important role of the cir-ITCH/miR-7/EGFR pathway in the migration and invasion of osteosarcoma cells and suggested that cir-ITCH may be a prognostic marker and a promising therapeutic target for osteosarcoma.

**Keywords**
cir-ITCH, miR-7, EGFR, migration, invasion, osteosarcoma

**Abbreviations**
CCK-8, Cell Counting Kit-8; circRNA, circular RNA; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; miRNA, microRNA; ncRNA, noncoding RNA; OS, osteosarcoma; PCR, polymerase chain reaction; qRT-PCT, quantitative real-time polymerase chain reaction

Received: September 7, 2019; Revised: October 22, 2019; Accepted: November 8, 2019.

**Introduction**

Osteosarcoma (OS) is the most common bone cancer and the third most frequent malignancy of adolescents and is characterized by poor survival.1 Moreover, in the past several decades, the treatment of OS has not changed. The main treatments are still surgery and nonspecific chemotherapy.2,3 Tumor cells can invade and migrate to other tissues, such as the brain and prostate, which is the main cause of death.4 The 5-year survival of patients with OS is only 10%, and metastasis is responsible for most deaths.5 The precise mechanisms of OS metastasis remain unclear and require further study. Understanding the mechanism would provide a theoretical basis for developing targeted therapy that could be designed to specifically inhibit the metastasis of OS.

An increasing number of studies have elucidated that non-coding RNAs (ncRNAs) play an important role in the progression of cancer.6 Circular RNAs (circRNAs) are a novel class of widely expressed and diverse RNAs that can regulate mammalian gene expression.7 CircRNAs are 100 bp to 4 kb in size and covalently closed loops with linked 5' and 3' ends, which helps to resist digestion by RNase.8,9 The main function of circRNA

1 Department of Orthopedics, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang, China

Corresponding Author:
Chunli Yang, Department of Orthopedics, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang, Jiangxi 330006, China.
Email: chunliyangmd@sina.com

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
is acting as a microRNA (miRNA) sponge and regulating the miRNA target genes through miRNA repression.10

Increasing evidence has shown that circRNAs play important roles in various cancer cellular activities, such as cell cycle progression, proliferation, and metastasis. Through the database analysis of circular RNA reported by Memczak et al.,11 we found that cir-ITCH spans several E3 ubiquitin (Ub) exons.9,12 The reports indicated that cir-ITCH has binding sites in many miRNAs, such as miR-214, miR-17, miR-7, miR-216b, and miR-128, suggesting that it may act as a miRNA sponge.10 It has been found that cir-ITCH plays an inhibitory role in both oesophageal squamous cell carcinoma and colorectal cancer and also suppresses lung cancer proliferation.12,13,14

In our research, we found that cir-ITCH was an oncogene that was upregulated in OS. Furthermore, cir-ITCH could decrease miR-7 expression levels, thereby leading to activation of the epidermal growth factor receptor (EGFR) pathway accompanied by high metastasis ability. This study revealed a critical role of cir-ITCH in OS progression and new mechanisms leading to OS invasion and metastasis.

Materials and Methods

Cell Culture

SJSA-1 and U2OS cells were obtained from Cell Bank, Type Culture Collection, Chinese Academy of Sciences (Shanghai, China). SJSA-1 cells were cultured with Dulbecco’s modified Eagle’s medium (DMEM) supplemented with glucose and 10% fetal bovine serum (FBS). U2OS cells were grown in McCoy 5A medium with 10% FBS. All cells were cultured in cell incubators with 5% CO2 at 37°C.

Plasmid Construction and Transfection

The sequence of cir-ITCH was cloned by polymerase chain reaction (PCR) and inserted into the pcDNA3.1 vector. All small interfering RNAs were obtained from RiboBio (Guangdong, China). The indicated cells were transiently transfected with 0.1 μmol/l mimics of miR-7 or control (Bioneer, Daejeon, Korea) with Lipofectamine 2000.

RNA Extraction and qRT-PCR Analysis

RNA was isolated using a Roche kit (Roche Applied Science, Basel, Switzerland) (TriPure Isolation Reagent). Complementary DNA (cDNA) was synthesized using a cDNA synthesis kit. Quantitative real-time polymerase chain reactions (qRT-PCRs) were carried out with a SYBR Green Kit (ABI, Warrington, United Kingdom). Glyceraldehyde 3-phosphate dehydrogenase was used as the endogenous reference gene. The results were confirmed by 3 independent experiments. The primer sequences have been published previously.1

| Gene       | Forward (5’-3’)                      | Reverse (5’-3’)                      |
|------------|--------------------------------------|--------------------------------------|
| cir-ITCH   | GCAGAGGCGCAACACTG-                   | TCCTTGAAAGCTGACT-                    |
|            | GAA                                  | TGGATTTGAGGAGAT-                     |
| Linear     | TAGACCAGAACCTCTCTCCTCCTG              | TAAAAGCTGAGATCT-                     |
| ITCH       | CCATGACCCTCTTTATGATG-                 | TGTTTATGCTCTCTT-                     |
| GAPDH      | GACAAGACTMGATGCTTTTGTTG-              | AGACTGTAGTGGTTG-                     |
| MiR-7      | TGGAAGACTMGATGCTTTTGTTG-              | AGACTGTAGTGGTTG-                     |

Cell Growth Assay

Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) was used to identify the cell growth rate. A total of 3000 cells were plated onto a 96-well plate. At day 0, day 1, day 2, day 3, and day 4, 10-μL CCK-8 was added to the medium, and the optical density at 450 nm was tested 2 hours later.

Wound-Healing Assay

Cells were placed onto 6-well cell culture dishes and cultured for 24 hours to achieve 100% confluence. Scratches were made by 200-μL pipette tips across the cell layers. The cells were washed with 10-mL phosphate-buffered saline solution 3 times and then incubated in serum-free media for 24 hours. At 0 and 24 hours, images were taken, and the gap length was calculated.

Cell Invasion Assays

Transwell assays with Matrigel were used to measure cancer cell invasion with different treatments. A total of 1 × 105 cancer cells were placed in the upper chamber with DMEM without FBS. Then, 700 μL of complete DMEM was added to the lower chamber. The noninvasive cells on the upper side of the membrane were removed after 48 hours. Subsequently, the membranes were fixed with 4% paraformaldehyde and 0.1% crystal violet.

Western Blot

Western blot analysis of lyzed OS cells was performed as previously described.2 Anti-EGFR, anti-phospho-EGFR 1068, anti-Erk1/2, and anti-phospho-Erk1/2 antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA), and anti-β-actin antibody was obtained from Merck Millipore Billerica.

Statistical Analyses

The results were analyzed by SPSS (Advanced statistical procedures companion, New Jersey, Prentice Hall Inc.Norusis) and GraphPad Prism (GraphPad Software, La Jolla, CA, USA). All the results are shown as the mean ± standard deviation. Differences between groups were calculated by Student t test.3 P < .05 was statistically significant.
Cir-ITCH Is Highly Expressed in OS

The existence and important functions of cir-ITCH in several cancers have been reported, and we speculated that cir-ITCH may contribute to the progression of OS. As there are no previous reports on the expression of cir-ITCH in OS, we carried out PCR to identify whether cir-ITCH was expressed in OS. A special characteristic of circRNAs is that they are resistant to degradation by RNase, which can degrade linear RNAs in a 3'-5' direction. The results showed that the linear ITCH messenger RNA was degraded by RNase, while cir-ITCH was resistant to it in the U2OS cell line (Figure 1A). This result confirmed the expression of cir-ITCH in the OS cell line. We also identified the expression of cir-ITCH in other OS cell lines by qRT-PCR. Compared to that in the human osteoblast hFOB 1.19 cell line, the expression of cir-ITCH was higher in OS cells (Figure 1B). In summary, we confirmed the presence of cir-ITCH in OS and found that cir-ITCH expression was higher in tumors than in normal cells.

Cir-ITCH Promotes the Growth of OS Cells

To investigate the roles of cir-ITCH in OS, we carried out RNA interference to knock down cir-ITCH expression in U2OS and SJSA-1 cells (Figure 2A and B) and transfected a cir-ITCH

Figure 1. The expression of cir-ITCH in osteosarcoma (OS). A, quantitative real-time polymerase chain reaction (qRT-PCR) was used to identify linear ITCH and cir-ITCH expression in the OS cancer cell line U2OS. B, qRT-PCR revealed the expression of cir-ITCH in different OS cell lines. Data are shown as the mean ± standard deviation (n = 3).

Figure 2. cir-ITCH promotes OS cell growth. A-B, quantitative real-time polymerase chain reaction (qRT-PCR) for cir-ITCH in U2OS (A) and SJSA-1 (B) cells treated with cir-ITCH or nonsense small interfering RNAs as described in the “Materials and Methods” section. C-D, qRT-PCR for cir-ITCH in 143b (C) and SAOS-2 cells (D), which were transfected with cir-ITCH vector or empty vector. E-F, Cell Counting Kit-8 (CCK-8) was used to determine the effect of cir-ITCH silencing on U2OS (E) and SJSA-1 cells (F). G-H, CCK-8 was used to detect the effect of cir-ITCH overexpression on 143b (G) and SAOS-2 cells (H). Data are shown as the mean ± standard deviation (n = 3, *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control).
overexpression plasmid into the 143b and SAOS-2 cell lines (Figure 2C and D). Cell Counting Kit-8 was used to identify the effect of cir-ITCH on OS cell growth. Silencing cir-ITCH impaired the proliferation of U2OS and SJSA-1 cells (Figure 2E and F), whereas overexpression of cir-ITCH promoted 143b and SAOS-2 cell growth (Figure 2G and H). We indicated that cir-ITCH could affect the growth rate of tumors by both overexpression and silencing of cir-ITCH.

Cir-ITCH Induces the Migration and Invasion of OS Cancer Cells

As metastasis is the main cause of death in patients with OS, we wanted to investigate whether cir-ITCH could influence the metastasis of OS. Due to the importance of migration and invasion in metastasis, we assessed the influence of cir-ITCH on OS migration by conducting a wound healing assay and identified invasion with a Transwell assay. The results showed that silencing cir-ITCH attenuated the migration and invasion of U2OS (Figure 3A and B) and SJSA-1 cells (Figure 3E and F), whereas overexpression of cir-ITCH promoted 143b and SAOS-2 cell growth (Figure 3C and D). We speculated that cir-ITCH could regulate the expression of a miRNA, as many previous reports have shown.\textsuperscript{6,11} We used miRanda and TargetScan software to predict cir-ITCH-binding miRNAs. The results showed that miR-17, miR-7, miR-128, miR-216b, and miR-214 may be potential target miRNAs of cir-ITCH. Then, we carried out qRT-PCR to investigate the influence of cir-ITCH on the miRNAs. The results showed that silencing cir-ITCH increased the expression of miR-7 in U2OS and SJSA-1 cells (Figure 4A and B), and re-expression of cir-ITCH blocked the expression of miR-7. In addition, overexpression of cir-ITCH decreased the expression of miR-7 (Figure 4C and D). Silencing of cir-ITCH could inhibit the growth, migration, and invasion of U2OS cells, while the inhibitor of miR-7 could block these effects on U2OS cells (Figure 4E and G). The function of miR-7 was also identified in SAOS-2 cells (Figure 4F and H). These findings indicate that cir-ITCH promotes OS metastasis and cell growth by inhibiting the level of miR-7.

Cir-ITCH Activates the EGFR/ERK Signaling Pathway via miR-7

As previous studies have shown that miR-7 could regulate the progression of several cancers through the EGFR pathway,\textsuperscript{15-18} we carried out Western blotting to confirm whether cir-ITCH could activate the EGFR pathway via miR-7, thereby increasing the growth and metastasis of OS cells. In U2OS cells, the
level of total and phosphorylation EGFR were downregulated with cir-ITCH silencing. Silence of cir-ITCH also led to the upregulation of E-cadherin and downregulation of N-cadherin (Figure 5A). The effects of cir-ITCH silencing were reversed by miR-7 inhibitors partially by EGFR/extracellular regulated protein kinases (ERK) activation (Figure 5C). On the other hand, overexpression of cir-ITCH increased EGFR protein level and activated EGFR/ERK pathway accompanied with E-cadherin upregulation and N-cadherin downregulation (Figure 5B), whereas the co-transfection of miR-7 mimics significantly reversed these effects in SAOS-2 cells (Figure 5D). These results showed a positive regulatory relationship between cir-ITCH and EGFR pathway activation.

The Cir-ITCH/miR-7/EGFR Axis Is Important for the Migration and Invasion of Osteosarcoma Cancer Cells

As the EGFR pathway plays important roles in metastasis of cancer, we confirmed the role of the EGFR pathway in cir-ITCH-induced metastasis by the addition of EGFR activator and inhibitor. As an activator of EGFR, epithelial growth factor (EGF) could block the reduction in metastasis induced by cir-ITCH silencing (Figure 6A and B). Conversely, erlotinib, an inhibitor of EGFR phosphorylation, blocked the cir-ITCH overexpression-induced metastasis of SAOS-2 cells (Figure 6C and D). These findings indicate that cir-ITCH activates the EGFR/ERK signaling pathway, leading to OS metastasis.

Discussion

Previously, cir-ITCH has been identified to repress the progression of oesophageal squamous cell carcinoma and colorectal cancer by the Wnt/β-catenin pathway. However, the function of cir-ITCH has not been elucidated in OS. In our research, we employed the human osteoblast cell line hFOB1.19 and several OS cancer cell lines. The results showed that the expression of cir-ITCH in OS cancer cell lines was upregulated significantly compared to that in the human osteoblast cell line as demonstrated by TaqMan-based qRT-PCR (Figure 1). These results suggest an important role for cir-ITCH in OS cancer.
In our study, CCK-8 assays showed that cir-ITCH mediated the promotion of cell growth. Moreover, the migration and invasion assay showed that cir-ITCH could promote the metastasis of OS cancer cells (Figures 2 and 3).

In 2013, Nature published 2 studies showing that circRNAs were newly found members of competing endogenous RNAs that could act as sponges of miRNA. CircRNAs can protect miRNA-targeted gene expression from degradation by interacting with miRNAs. Considering the function of circRNA, we speculated that cir-ITCH may act as a miRNA sponge to regulate miRNA expression. In our study, the qRT-PCR results showed that cir-ITCH could reduce the expression of miR-7, while the exact mechanism of the regulation remained to be investigated. Our research determined that cir-ITCH influenced the growth and metastasis of OS cells through miR-7 (Figure 4). We also confirmed the hypothesis with the rescue experiments in our research.

As research has shown that miR-7 can regulate drug resistance and progression in several cancers through the EGFR pathway, we further investigated the role of miR-7 and EGFR in OS. We found that cir-ITCH increased the EGFR protein level, which was consistent with the report that EGFR

**Figure 5.** cir-ITCH increases EGFR protein levels and activates the EGFR/ERK pathway. A, Western blot was performed to identify the expression of EGFR/p-EGFR, ERK/p-ERK, and EMT markers in U2OS NC and si-cir-ITCH cells. B, Western blot was performed to identify the expression of EGFR/p-EGFR, ERK/p-ERK, and EMT markers in SAOS-2 cells transfected with control vector or cir-ITCH vector. C, The relative levels of the indicated proteins were analyzed by Western blot in U2OS2 NC and si-cir-ITCH cells treated with miR-7 inhibitor. D, The relative levels of the indicated proteins were analyzed by Western blot in SAOS-2 NC and OE-cir-ITCH cells transfected with NC and miR-7 mimics.
is a target gene of miR-7, and silencing cir-ITCH decreased the expression of EGFR in OS cells. EGFR is the receptor of EGF and is important for various cell signaling pathways. EGFR belongs to the ErbB receptor family, which includes ErbB-1, ErbB-2, ErbB-3, and ErbB-4. EGFR is also known as ErbB1 and HER1, and its mutation or overexpression generally triggers tumor development.\textsuperscript{16,17} Our results showed that miR-7 could decrease the protein level of EGFR accompanied by the reduction in EGFR phosphorylation (Figure 5). Inhibition of the EGFR pathway blocked the cir-ITCH-induced metastasis of OS cells (Figure 6). Thus, the rescue experiments verified that cir-ITCH promoted OS proliferation and metastasis through the cir-ITCH/miR-7/EGFR axis.

In future research work, we will further analyze the expression of cir-ITCH in patient tissues and its relationship with survival. We will also verify the relationship between this signaling pathway and metastasis in patient specimens and animal models.

As a rising star, circRNAs may play critical roles in diseases, especially in various cancers. Our research showed that cir-ITCH was abnormally highly expressed in OS. Furthermore, the cir-ITCH/miR-7/EGFR signaling pathway mediated the growth and metastasis of OS cells, which provided theoretical insight into the roles of circRNAs in the progression of OS. Thus, cir-ITCH may serve as a new biomarker and therapeutic target for OS.

**Authors' Note**

Our experiments did not involve patient and animal experiments.

Figure 6. EGFR pathway activation promotes the migration and invasion of osteosarcoma cells. A-B, Wound healing assays and invasion assays were performed to identify the metastasis of U2OS cells treated with or without EGF (10 ng/mL). C-D, Migration and invasion assays were carried out to detect the metastasis of SAOS-2 cells treated with or without erlotinib (10 ng/mL).
Acknowledgments

Thanks to all the authors. Thanks to the good working environment provided by hospitals and laboratories

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Chunli Yang  https://orcid.org/0000-0001-6858-6587

References

1. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007;26(1):1-18.
2. Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, et al. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese musculoskeletal oncology group study. J Clin Oncol. 2002;20(16):3470-3477.
3. Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2003;21(10):2011-2018.
4. Evola FR, Costarella L, Pavone V, et al. Biomarkers of osteosarcoma, chondrosarcoma, and Ewing sarcoma. Front Pharmacol. 2017;8:150.
5. Friebel JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL. Osteosarcoma: a meta-analysis and review of the literature. Am J Orthop. 2015;44(12):547-553.
6. Adams BD, Parsons C, Walker L, Zhang WC, Slack FI. Targeting noncoding RNAs in disease. J Clin Invest. 2017;127(3):761-771.
7. Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Res. 2013;73(18):5609-5612.
8. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. Plos One. 2012;7(2):e30733.
9. Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141-157.
10. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384-388.
11. Memczak S, Jens M, Elefsvioni A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333-338.
12. Li F, Zhang L, Li W, et al. Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway. Oncotarget. 2015;6(8):6001-6013.
13. Huang G, Zhu H, Shi Y, Wu W, Cai H, Chen X. cir-ITCH plays an inhibitory role in colorectal cancer by regulating the Wnt/β-catenin pathway. Plos One. 2015;10(6):e0131225.
14. Wu L, Zhang L, Fan K, Cheng ZX, Sun QC, Wang JJ. Circular RNA-ITCH suppresses lung cancer proliferation via inhibiting the Wnt/β-catenin pathway. J Clin Invest. 2016(1):1579490.
15. Jin W, Xu HX, Zhang SR, et al. Tumor-infiltrating NETs predict postsurgical survival in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019;26(2):635-643.
16. Sun X, Li J, Sun Y, et al. miR-7 reverses the resistance to BRAF in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget. 2016;7(33):53558-53570.
17. Liu X, Li G, Su Z, et al. Poly(amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells. Oncol Rep. 2013;29(4):1387-1394.
18. Suto T, Yokobori T, Yajima R, et al. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 2015;36(3):338-345.
19. Liu TT, Bi JW, Wang J. Relationship between EGFR mutation and brain metastasis in non-small cell lung cancer. Cancer Res Prev Treat. 2017;44(3):189-192.
20. Jin W, Liao X, Lv Y, et al. MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner. Cell Death Dis. 2017;8(8):e2980.